

Date: June 20, 2026

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

Scrip Code: REMUS

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with sub-para 20 of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Espee Biopharma & Finechem LLC, Stepdown Subsidiary of the Company (“EBFL”) has received a notice from Department of the Treasury Internal Revenue Service, Ogden, UT 84201-0039, imposing the penalty due to alleged non-payment of tax and late filing of tax due.

EBFL believes that since the said tax has already been paid there is no case of imposing of penalty. Additionally, EBFL is in the process of engaging with the IRS to seek necessary clarifications and corrections, as applicable.

The details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as **Annexure-I** for your reference. We request you to take the above information on record.

Thanking you.

Yours faithfully,
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl: As Above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Annexure – I

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular NO. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026

Sr. No.	Particulars	Description
1.	Name of Authority	Department of the Treasury Internal Revenue Service, Ogden, UT 84201-0039 (“IRS”).
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Penalty on alleged non-payment of tax imposed by IRS on Espee Biopharma & Finechem LLC, Stepdown Subsidiary of the Company (“EBFL”).
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Notice dated June 15, 2026, received on June 19, 2026.
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Due to alleged non-payment of tax and late filing of tax by EBFL to IRS, a penalty of USD 14,247.38 has been imposed on EBFL.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on financials, operations or other activities of the Company and EBFL due to the said notice. EBFL believes that since the said tax has already been paid there is no case of imposing of penalty. EBFL is in process of taking up the matter with IRS for necessary corrections.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536